European Thyroid Journal (Oct 2023)

Radiofrequency ablation for thyroid Bethesda III nodules: preliminary results

  • Pi-Ling Chiang,
  • Sheng-Dean Luo,
  • Yen-Hsiang Chang,
  • Chen-Kai Chou,
  • Shun-Yu Chi,
  • Yi-Fan Chen,
  • Wei-Che Lin

DOI
https://doi.org/10.1530/ETJ-23-0105
Journal volume & issue
Vol. 12, no. 6
pp. 1 – 7

Abstract

Read online

Purpose: The purpose of this study was to evaluate the feasibility of radiofrequency ablation (RFA) for thyroid nodules with cytological atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS, Bethesda III). Materials and methods: A total of 28 adults presenting with 30 initial Bethesda III nodules underwent thyroid RFA at a single medical center. Thyroid nodules with Bethesda IV or V according to the second aspiration were excluded. All RFA procedures were performed using the free-hand, ‘moving-shot’ technique under local anesthesia. Clinical features and demographics, RFA details, nodule volume reduction rate (VR R), and complications were analyzed. Results: The mean age of patients was 47.6 years, 82.1% of whom were females. Mean nodule volumes at pre-RFA, and at 6 months and 12 months post-R FA were 7.92, 2.42, and 1.25 mL, respectively, with a VRR of 77.9% at 6 months, and 87.4% at 12 months. Post-RFA complications were noted in two patients, one with transient vocal cord palsy and another with isthmus minor rupture. Conclusion: RFA may be another safe alternative except for active surveillance or surgical excision for AUS/FLUS nodules with low-suspicion Thyroid Imagin g Reporting and Data System features for patients who are unsuitable or strongly ref use surgery. Long-term results remain uncertain, thus further follow-up study is necessary.

Keywords